Background: Tranexamic acid is a lysine analogue that acts by blocking the lysine-dependent production of plasmin and resultant fibrinolysis. Plasmin has direct effects on immune function and inflammation, and we have compelling laboratory and clinical evidence demonstrating tranexamic acid may reduce infection risk in surgery.
Design: This multicentre, pragmatic, double-blind, randomised clinical trial will compare the incidence of surgical site infection and red cell transfusion requirements after IV tranexamic acid and placebo in patients undergoing gastrointestinal surgery.
Study intervention: A bolus of study drug, 0.15 ml/kg (TxA 15 mg/kg or matched placebo) before surgical incision, and then infusion at 0.05 ml/kg/h until the end of surgery. All other aspects of anaesthesia and surgery are flexible.
Entry criteria: Adult patients scheduled for elective or semi-elective open or lap-assisted gastrointestinal surgery (oesophageal, gastric, hepatobiliary, pancreatic, colorectal)

Project Information


Alfred Health



Infectious Diseases

General Surgery

End date:

Can this be done remotely?


Senior clinician

Parts of research done:

Literature review, Research proposal, Ethics approval

Positions Available:

Principal Investigators

Current Funding:

NHMRC $1000 per completed patient

Prospective researchers receive:


  • Twitter

Project owner

Sophie Wallace

Please fill out the form below to express your interest in this research project. It is free to contact a project owner and express interest in a project. We recommend writing a detailed message regarding why you are interested in the project (e.g. what skills you can bring to the team) or what information you are seeking (e.g. detail regarding the study duration). All information you provide will be shared with the primary researcher, including your contact details. Thank you for your interest in this project.




VIC. 3002



0424 730 627

ABN: 77 640 321 295


  • Twitter
  • White Facebook Icon
  • White Instagram Icon
  • LinkedIn - White Circle